PHILADELPHIA—Ever since the seminal work of C. Lockard Conley, MD, in 1952 of the discovery of the lupus anticoagulant, antiphospholipid syndrome (APS) has been of great interest to rheumatologists, hematologists and many others. At ACR Convergence 2022, the session titled Draft ACR/EULAR Antiphospholipid Syndrome Classification Criteria sought to summarize the rigorous process that went into…
PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing…
PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
Research from Gloersen et al. suggests the systemic effects of obesity, as measured by leptin, may play a role in the severity of pain experienced by patients with hand osteoarthritis.
The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.
Editor’s note: This has been extended from the print version to include additional background information on each recipient. Each year, the ACR honors up to 10 clinical and research fellows who have performed meritoriously. Meet this year’s Distinguished Fellows, who are bridging the gap between research and patient care, and who were recognized at ACR…
Uzma Haque, MD, addressed the management of difficult-to-treat rheumatoid arthritis, using patient case reports to demonstrate clinical decision-making, during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
Glucocorticoids remain a prominent part of care for many patients with SLE but can have toxic side effects; this EULAR 2022 session discussed one institution’s approach to lower the dosage.